Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia

Megan M Cleary, B.S., B.A., Rhese Thompson, Shawn Mahmood, B.S., B.A., Monika Davare, PhD, Steve Kurtz, PhD, Johannes Elferich, PhD, Ujwal Shinde, PhD, Brian J. Druker, MD, Jack Singer, MD, Anupriya Agarwal, PhD

Blood (2015) 126 (23): 570.

https://doi.org/10.1182/blood.V126.23.570.570

Published: 2015

Journal Articles

Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation

Brian C Betts, MD, David Bastian, Hung Nguyen, PhD, Jessica Lauren Heinrichs, BS, MS, Yongxia Wu, MD PhD, Anandharaman Veerapathran, PhD, Marie C Lee, MD, Jack Singer, MD, Claudio Anasetti, MD, Xue-Zhong Yu, MD MS

Blood (2015) 126 (23): 1874.

https://doi.org/10.1182/blood.V126.23.1874.1874

Published: 2015

Journal Articles

Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis

Jack Singer, MD, Suliman Al-Fayoumi, PhD MBA, Haiching Ma, Rami S Komrokji, MD, Ruben Mesa, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 1874.

https://doi.org/10.1182/blood.V124.21.1874.1874

Published: 2014

Journal Articles

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Raya Mawad, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Bart L Scott, MD, Brent L. Wood, MD PhD, Carol Dean, MPH, BSN, Vicky Sandhu, MD MPH, H. Joachim Deeg, MD, Roland B. Walter, MD PhD MS, Lixia Wang, PhD, Jack Singer, MD, Elihu H. Estey, MD, John Pagel, MD PhD

Blood (2014) 124 (21): 3690.

https://doi.org/10.1182/blood.V124.21.3690.3690

Published: 2014

Journal Articles

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Pamela S. Becker, MD, PhD, Paul C. Hendrie, MD, PhD, Bart L Scott, MD, Brent L. Wood, MD, PhD, Carol Dean, RN, Ravinder K Sandhu, MD, H. Joachim Deeg, MD, Roland B. Walter, MD, PhD, Frederick R. Appelbaum, MD, Lixia Wang, PhD, Han Myint, MD, Jack Singer, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 3926.

https://doi.org/10.1182/blood.V122.21.3926.3926

Published: 2013

Journal Articles

Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells

Chirag Acharya, Mike Y Zhong, B.S., Daniel Tannenbaum, B.S., Michelle Chen, Matt Ma, Jack Singer, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Yu-Tzu Tai, PhD

Blood (2012) 120 (21): 1847.

https://doi.org/10.1182/blood.V120.21.1847.1847

Published: 2012

Journal Articles

Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment

Emanuela Salvatorelli, MD, Odalys Gonzalez Paz, PhD, Elvio Covino, MD, Massimo Chello, MD, Jack Singer, MD, Pierantonio Menna, PhD, Giorgio Minotti, MD

Blood (2011) 118 (21): 4966.

https://doi.org/10.1182/blood.V118.21.4966.4966

Published: 2011

Journal Articles

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Raoul Herbrecht, David MacDonald, MD, FRCPC, Florian Weissinger, MD, Martin Wilhelm, MD, Charles Holladay, MS, MD, Nam H. Dang, MD, PhD, Peter Holman, MD, Paul Cernohous, MS, Jack Singer, MD, Richard H. van der Jagt, MD, FRCPC

Blood (2011) 118 (21): 1605.

https://doi.org/10.1182/blood.V118.21.1605.1605

Published: 2011

Journal Articles

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Ruth Pettengell, FRACP, PhD, Pier Luigi Zinzani, MD, PhD, Geetha Narayanan, MD, Fernando Hurtado de Mendoza, MD, Raghunadharao Digumarti, MD, Henry Gomez, MD, Bertrand Coiffier, MD, PhD, Gary Schiller, MD, David A. Rizzieri, MD, Paul Cernohous, MS, Lixia Wang, PhD, Jack Singer, MD

Blood (2010) 116 (21): 2833.

https://doi.org/10.1182/blood.V116.21.2833.2833

Published: 2010

Journal Articles

Pixantrone Dimaleate (PIX) and Comparators In the Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (aNHL): An Analysis of Response and Survival by Gender and Age

Jack Singer, MD, Paul Cernohous, MS, Gabor Jurida, MD, Lixia Wang, PhD, Christine Kuepfer, MS, Ruth Pettengell, FRACP, PhD

Blood (2010) 116 (21): 4883.

https://doi.org/10.1182/blood.V116.21.4883.4883

Published: 2010

NARROW

Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia

Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation

Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells

Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Pixantrone Dimaleate (PIX) and Comparators In the Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (aNHL): An Analysis of Response and Survival by Gender and Age

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only